125 related articles for article (PubMed ID: 22983311)
1. Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials.
Castells X; Cunill R; Capellà D
Eur J Clin Pharmacol; 2013 Mar; 69(3):347-56. PubMed ID: 22983311
[TBL] [Abstract][Full Text] [Related]
2. Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study.
Inglis SK; Carucci S; Garas P; Häge A; Banaschewski T; Buitelaar JK; Dittmann RW; Falissard B; Hollis C; Kovshoff H; Liddle E; McCarthy S; Nagy P; Neubert A; Rosenthal E; Sonuga-Barke E; Wong I; Zuddas A; Coghill DC;
BMJ Open; 2016 Apr; 6(4):e010433. PubMed ID: 27118284
[TBL] [Abstract][Full Text] [Related]
3. Methodological advantages and disadvantages of parallel and crossover randomised clinical trials on methylphenidate for attention deficit hyperactivity disorder: a systematic review and meta-analyses.
Krogh HB; Storebø OJ; Faltinsen E; Todorovac A; Ydedahl-Jensen E; Magnusson FL; Holmskov M; Gerner T; Gluud C; Simonsen E
BMJ Open; 2019 Mar; 9(3):e026478. PubMed ID: 30928951
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: A systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials.
Holmskov M; Storebø OJ; Moreira-Maia CR; Ramstad E; Magnusson FL; Krogh HB; Groth C; Gillies D; Zwi M; Skoog M; Gluud C; Simonsen E
PLoS One; 2017; 12(6):e0178187. PubMed ID: 28617801
[TBL] [Abstract][Full Text] [Related]
5. Evaluating serdexmethylphenidate and dexmethylphenidate capsules as a once-daily treatment option for ADHD.
Barnhardt EA; Narayanan AR; Coury DL
Expert Opin Pharmacother; 2023; 24(11):1215-1219. PubMed ID: 37226489
[TBL] [Abstract][Full Text] [Related]
6. [A scientifically grounded pharmacological treatment of ADHD].
Vertessen K
Ned Tijdschr Geneeskd; 2023 Dec; 168():. PubMed ID: 38175554
[TBL] [Abstract][Full Text] [Related]
7. Hallucinations and other psychotic symptoms in response to methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder: a Cochrane systematic review with meta-analysis and trial sequential analysis
Ramstad E; Storebø OJ; Gerner T; Krogh HB; Holmskov M; Magnusson FL; Moreira-Maia CR; Skoog M; Groth C; Gillies D; Zwi M; Kirubakaran R; Gluud C; Simonsen E
Scand J Child Adolesc Psychiatr Psychol; 2018; 6(1):52-71. PubMed ID: 33520751
[TBL] [Abstract][Full Text] [Related]
8. Can Adverse Event Patterns Inform Shared Decision-Making in ADHD Treatment? A Systematic Review of Evidence From Registration Trials for FDA-Approved Treatments in Adults.
Bond JB; Walsh DM; Surman CBH
J Psychiatr Pract; 2024 May; 30(3):172-180. PubMed ID: 38819241
[TBL] [Abstract][Full Text] [Related]
9. Differences between centers in functional outcome of patients with ADHD after 1 year from the time of diagnosis.
Cartabia M; Finazzi S; Bonati M;
Sci Rep; 2023 Oct; 13(1):18738. PubMed ID: 37907548
[TBL] [Abstract][Full Text] [Related]
10. Decision aid development and its acceptability among adults with attention-deficit/hyperactivity disorders regarding treatment discontinuation after remission.
Tsujii N; Okada T; Usami M; Kuwabara H; Fujita J; Negoro H; Iida J; Aoki Y; Takaesu Y; Saito T
PCN Rep; 2022 Dec; 1(4):e57. PubMed ID: 38868662
[TBL] [Abstract][Full Text] [Related]
11. Severe muscle pain and stiffness due to dexmethylphenidate.
Kon JJ; Kon AA
Clin Case Rep; 2020 Mar; 8(3):420-422. PubMed ID: 32185027
[TBL] [Abstract][Full Text] [Related]
12. Occurrence of psychotic symptoms during treatment of ADHD with methylphenidate: Clinical significance and the need for further research.
Reiersen AM
Scand J Child Adolesc Psychiatr Psychol; 2018; 6(1):1-3. PubMed ID: 33520746
[No Abstract] [Full Text] [Related]
13. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Epstein T; Patsopoulos NA; Weiser M
Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression.
Cunill R; Castells X; Tobias A; Capellà D
Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):961-9. PubMed ID: 23813665
[TBL] [Abstract][Full Text] [Related]
15. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments.
Sonuga-Barke EJ; Brandeis D; Cortese S; Daley D; Ferrin M; Holtmann M; Stevenson J; Danckaerts M; van der Oord S; Döpfner M; Dittmann RW; Simonoff E; Zuddas A; Banaschewski T; Buitelaar J; Coghill D; Hollis C; Konofal E; Lecendreux M; Wong IC; Sergeant J;
Am J Psychiatry; 2013 Mar; 170(3):275-89. PubMed ID: 23360949
[TBL] [Abstract][Full Text] [Related]
16. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
Martinez-Raga J; Knecht C; Szerman N; Martinez MI
CNS Drugs; 2013 Jan; 27(1):15-30. PubMed ID: 23160939
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
Hennissen L; Bakker MJ; Banaschewski T; Carucci S; Coghill D; Danckaerts M; Dittmann RW; Hollis C; Kovshoff H; McCarthy S; Nagy P; Sonuga-Barke E; Wong IC; Zuddas A; Rosenthal E; Buitelaar JK;
CNS Drugs; 2017 Mar; 31(3):199-215. PubMed ID: 28236285
[TBL] [Abstract][Full Text] [Related]
18. A systematic meta-review of systematic reviews on attention deficit hyperactivity disorder.
Chaulagain A; Lyhmann I; Halmøy A; Widding-Havneraas T; Nyttingnes O; Bjelland I; Mykletun A
Eur Psychiatry; 2023 Nov; 66(1):e90. PubMed ID: 37974470
[TBL] [Abstract][Full Text] [Related]
19. Cognitive control enhancement in attention deficit hyperactivity disorder (ADHD) and neurotypical individuals.
Weinberg H; Baruch Y; Tzameret H; Lavidor M
Exp Brain Res; 2023 Sep; 241(9):2381-2392. PubMed ID: 37624418
[TBL] [Abstract][Full Text] [Related]
20. Influence of
Śmiarowska M; Brzuchalski B; Grzywacz E; Malinowski D; Machoy-Mokrzyńska A; Pierzchlińska A; Białecka M
Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
